Biote expects full-year 2026 revenue above $175 million.
Third-quarter procedure revenue declined 15.1% year over year to $28.9 million.
Internal facility Xteria Health now supplies over 50% of shipped pellets.
On its third-quarter 2026 earnings call, held on Nov. 4, 2026, biote (NASDAQ:BTMD) announced full-year 2026 revenue guidance above $175 million despite a 9.6% year-over-year quarterly revenue decline to $43.3 million. Revenue contracted after a January 2026 voluntary product recall delayed new clinic onboarding and clinical procedure volume.
Three takeaways from the call stand out for long-term investors.
Management is deploying data analytics to identify clinics needing operational support and to enforce sales team accountability. Directing field representatives toward lagging practices aims to reduce clinic attrition and rebuild procedure volume.
To accelerate our progress and optimize our decision making, we are leveraging our investments in data and analytics to identify clinics that need additional support so that we can direct our resources where we believe they will have the greatest and most immediate impact.
-- Bob Peterson, Chief Executive Officer and Chief Financial Officer
Retaining healthcare providers requires ongoing clinical education beyond initial onboarding. Management is structuring science-based resources to address common clinical questions, aiming to cement long-term practitioner trust across its network.
Ultimately, I want practitioners to view Biote as a continuing source of clinical expertise and support throughout their relationship with us.
-- Dr. Komal Bajaj, Chief Medical Officer
Gross margin, the percentage of revenue left after direct production costs, dropped to 67.7% due to temporary reliance on third-party suppliers. Production at Xteria Health, the company's internal manufacturing facility, has recovered to pre-recall levels to supply over 50% of shipped pellets.
For perspective, as of today, Xteria Health has returned to pre recall levels and will supply over 50% of our shipped pellets as compared to 30% in the second quarter of 26.
-- Bob Peterson, Chief Executive Officer and Chief Financial Officer
Procedure volume shows early signs of stabilizing across clinics. The company relies on internal manufacturing, expanded field representatives, and clinical education to rebuild procedure counts while tracking clinic retention and pricing discipline.
While recent procedure trends are encouraging, and help support our 2026 outlook, We have further work to do to achieve the results we believe are possible.
-- Bob Peterson, Chief Executive Officer and Chief Financial Officer
Long-term performance hinges on converting clinic relationships into consistent procedure volume across the network.
By concentrating on these metrics, we aim to enhance our execution and generate stronger financial performance over time.
-- Bob Peterson, Chief Executive Officer and Chief Financial Officer
Before you buy stock in Biote, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Biote wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $335,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,000,640!*
Now, it’s worth noting Stock Advisor’s total average return is 823% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 16, 2026.
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.